ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0594

The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study

Titilola Falasinnu1, Nada Rizk1, Becca Feldman2, Devy Zisman3, Michael Leshchinsky2, Gabriella Lawrence2, Yashaar Chaichian4 and Julia Simard1, 1Stanford School of Medicine, Stanford, CA, 2Clalit Research Institute, Clalit Health Services, Ramat Gan, Israel, 3Carmel Medical Center, Haifa, Israel, 4Stanford University, Los Gatos, CA

Meeting: ACR Convergence 2021

Keywords: Disparities, Epidemiology, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 7, 2021

Title: Healthcare Disparities in Rheumatology Poster (0594–0622)

Session Type: Poster Session B

Session Time: 8:30AM-10:30AM

Background/Purpose: Misclassification of race and ethnicity in data can impact how disparities in prevalence, incidence, severity, and complications of systemic lupus erythematosus (SLE) are interpreted. Categorizing and labeling individuals’ race/ethnicity is often limited to preset options. Consequently, in many regions, people of Middle Eastern descent are asked to choose between “White” and “Other.” Our objective was to use population-based data from Israel to characterize the burden of SLE in the population by infrequently examined race/ethnic groups (i.e. Sephardi, Ashkenazi, Ethiopian, Arab/Bedouin, and Mixed ancestry).

Methods: A cohort of patients with SLE was identified using electronic health record data between 2010 and 2017 from Clalit Health Services (CHS), the largest healthcare provider in Israel comprising 53% of the adult population (4.7 million patients). SLE prevalence was estimated on January 1, 2017 and annual incidence was examined over time for several SLE definitions by sex, age, and ethnicity. Ethnicity (Sephardi, Ashkenazi, Ethiopian, Arab/Bedouin, Mixed Jews, Unknown) was defined using data on four grandparents; and categorized those with more than one noted ethnicity among grandparents as “mixed”, while those missing 2 or more grandparents was “unknown”. We used SLE definitions from the existing literature and added serologic testing to generate six definitions varying in sensitivity and specificity (Fig 1). These definitions incorporated ICD9 coded inpatient and outpatient visits, provider type/specialty, number of SLE-coded visits, and serologic testing (including antinuclear antibody positivity, anti-double stranded DNA antibodies, and low C3 and C4).

Results: In total, our study population included up to 6,267 potential SLE cases and 404,838 comparators from the CHS membership. The distribution of sociodemographic factors varied little between case Definitions 2 and 5 (Table 1). The prevalent cases, regardless of definition, were older and more likely to be female, have hypertension, diabetes, and kidney disease than the general CHS comparator group. Overall prevalence on January 1, 2017 ranged from 155 cases per 100,000 to 49 cases per 100,000 depending on the sensitivity vs specificity of the definition. Women comprised the majority of prevalent and incident cases across all age groups, and prevalence increased with age. Among children (0-15y) prevalence was highest among Arab/Bedouin and Sephardic groups (Figure 2). Among 16-49 year-olds, prevalence was highest among Sephardi and those of unknown ethnicity. Among those 50+ years, prevalence was highest among those of mixed ancestry. Individuals with Ethiopian ancestry had the lowest prevalence in all age groups. Overall incidence was highest in Sephardi and Arab/Bedouin groups (data not shown).

Conclusion: In our retrospective study, the burden of SLE in Israel appeared to vary by race/ethnicity and age. Notably, differences in SLE prevalence and incidence became apparent when groups that are typically misclassified as “White” or “Other” were further stratified into their racial and ethnic groups.

Figure 1. SLE Case Definition Classifications from most sensitive to most specific. *

Table 1. Characteristics of prevalent SLE cases in Clalit Health Services (CHS) vs random sample of general CHS membership during follow-up

Figure 2. SLE Prevalence (per 100,000) by age and race/ethnicity in Clalit Health Services, Jan 1, 2017


Disclosures: T. Falasinnu, None; N. Rizk, None; B. Feldman, None; D. Zisman, None; M. Leshchinsky, None; G. Lawrence, None; Y. Chaichian, GSK, 12, Attendee, Academic Teaching Institution Needs Assessment Advisory Board meeting, on 12/7/19., Lupus Research Alliance, 12, Lupus Clinical Investigators Network (LuCIN) site Director at Stanford since April 2020. Research support paid through Stanford related to SLE and LuCIN-sanctioned clinical trials., Gilead Sciences, 12, Previously served as a study investigator at Stanford for a lupus nephritis trial., Pfizer, 12, Prior sub-investigator on a pilot project in RA at Stanford in collaboration with Pfizer., Amgen Inc., 12, I serve as PI at Stanford for a multicenter lupus clinical trial.; J. Simard, None.

To cite this abstract in AMA style:

Falasinnu T, Rizk N, Feldman B, Zisman D, Leshchinsky M, Lawrence G, Chaichian Y, Simard J. The Burden of Systemic Lupus in Five Distinct Racial and Ethnic Groups in Israel: A Population-based Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/the-burden-of-systemic-lupus-in-five-distinct-racial-and-ethnic-groups-in-israel-a-population-based-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-burden-of-systemic-lupus-in-five-distinct-racial-and-ethnic-groups-in-israel-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology